Novel cancer therapies: blocking the cells that control tumour growth

Researchers at Hudson Institute of Medical Research have identified a mechanism by which cancer cells are able to invade and spread, and are targeting this in the treatment of cancer.

Summary

The Hudson team has discovered a molecule expressed by cancer cells that is critical for the implantation and invasion of tumours into underlying healthy tissue. Using *in vitro* and *in vivo* models, they have shown that blocking this molecule prevents invasion into the basement membrane level and thus prevents metastasis.

The team is developing this work towards a novel, effective anti-cancer strategy that can stabilise or regress disease and enhance the effectiveness of existing treatments for cancer. A direct inhibitor of metastasis will profoundly reduce cancer-related mortality, and will increase survival time for patients with primary or recurrent disease.

Targeting leader cells to prevent spread

Ovarian cancer is often diagnosed at a late stage of disease, when it has spread beyond the ovaries to other organs in the peritoneal cavity. This spread can occur through cellular aggregates that break off from the tumour site, and then attach and invade into other locations. The ability of these aggregates to form tumour deposits and invade into healthy tissue is controlled by leader cells. Therapies that target these leader cells are likely to be key in achieving effective, sustained remission of disease.

Our researchers have recently found that leader cells in ovarian cancer are enriched for the protein KRT14. In addition, KRT14 was found to be essential for the invasion of ovarian cancer cells into the basement membrane level and subsequent development of a tumour.

The team are currently developing a monoclonal antibody that targets a portion of KRT14 to inhibit the invasion process.

The antibody they are developing, mAb-KRT, has shown potent efficacy in orthotopic syngeneic mouse models of ovarian cancer, in the absence of toxicity, and is active against both chemo-resistant and chemo-naive disease.

Development pathway

Our team have identified a lead candidate monoclonal antibody for inhibition of the target, and are progressing through preclinical studies. They are currently seeking opportunities for co-investment, licensing or collaboration to further develop this cancer treatment program.

Applications

Many tumour types employ this mechanism of invasion. Ovarian cancer is an example of particular need.

Ovarian cancer is the eighth most common cancer overall among women, and is the most common cause of death from a gynaecological cancer.

Current standard treatment options for women with ovarian cancer include surgery with chemotherapy. Because there is no early detection or screening test for ovarian cancer, most cases are diagnosed at an advanced stage of disease, when the 5-year survival rate is only 43%. In many cases disease is no longer confined to the ovaries and has spread to other organs in the peritoneal cavity. Approximately 75% of patients will relapse, often with chemotherapy-resistant disease which limits treatment options further.

There is an urgent and unmet need for novel therapeutic options aimed at preventing the spread of metastatic disease, to improve the management and long-term survival of cancer patients.

Key data



Administration of novel mAb-KRT causes direct regression of established tumour mass in mice. Mice (n=10/group) with established primary ovarian tumours were administered mAb-KRT in bi-weekly 5mg/kg doses IP. Controls received either isotype-matched control antibody or PBS vehicle alone. After 3 weeks of continued treatment all animals were culled and examined, and tumour mass measured. At completion, mice treated with mAb-KRT had no detectable tumours whereas cancers remained in both isotype-treated and untreated vehicle control mice (mean +/-SD).

IP position

International patent application filed.

Contact us

e: commercialisation@hudson.org.au
t: +61 3 8572 2008
w: https://hudson.org.au/commercialisation/

Team

This project is managed by Dr Maree Bilandzic and Dr Andrew Stephens from Hudson's Ovarian Cancer Biomarkers research group.

Dr Andrew Stephens leads the Ovarian Cancer Biomarker research group at Hudson Institute. He is one of Australia's foremost experts in the field of ovarian cancer research, with a strong background in biochemistry, molecular biology and mass spectrometry, and an established track record in their application to investigate gynaecological disease.

Dr Maree Bilandzic is a Senior Research Fellow at Hudson and has extensive experience in ovarian cancer research, with a particular focus on understanding pathways controlling critical stages of metastasis. She has developed unique laboratory models to examine these events in real-time, key to examining how early cell-cell interactions dictate disease progression.

Related publication

Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells. Bilandzic M … Stephens AN, 2019 *Cancers* doi:10.3390/cancers11091228

Hudson Institute of Medical Research

Hudson Institute of Medical Research is a leading Australian medical research institute recognised internationally for research into reproductive health and pregnancy, infant and child health, inflammation, and cancer. Our research programs span discovery science and translational research, and clinical trials.

Our worldwide scientific and medical collaborations provide a foundation for transformative healthcare programs across the globe, with our researchers leading developments in cell therapies, women's health, microbiome research, diagnostics, and cancer.

Partnership opportunities include:

- Therapeutics, including oncology and gene therapy
- Reproductive, women's and children's health
- Regenerative medicine
- Inflammation and immunology
- Diagnostics and biomarkers